1
|
Zinc Regulates Glucose Metabolism of the Spinal Cord and Neurons and Promotes Functional Recovery after Spinal Cord Injury through the AMPK Signaling Pathway. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2021; 2021:4331625. [PMID: 34373765 PMCID: PMC8349299 DOI: 10.1155/2021/4331625] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 06/19/2021] [Indexed: 12/17/2022]
Abstract
Spinal cord injury (SCI) is a traumatic disease that can cause severe nervous system dysfunction. SCI often causes spinal cord mitochondrial dysfunction and produces glucose metabolism disorders, which affect neuronal survival. Zinc is an essential trace element in the human body and plays multiple roles in the nervous system. This experiment is intended to evaluate whether zinc can regulate the spinal cord and neuronal glucose metabolism and promote motor functional recovery after SCI. Then we explore its molecular mechanism. We evaluated the function of zinc from the aspects of glucose uptake and the protection of the mitochondria in vivo and in vitro. The results showed that zinc elevated the expression level of GLUT4 and promoted glucose uptake. Zinc enhanced the expression of proteins such as PGC-1α and NRF2, reduced oxidative stress, and promoted mitochondrial production. In addition, zinc decreased neuronal apoptosis and promoted the recovery of motor function in SCI mice. After administration of AMPK inhibitor, the therapeutic effect of zinc was reversed. Therefore, we concluded that zinc regulated the glucose metabolism of the spinal cord and neurons and promoted functional recovery after SCI through the AMPK pathway, which is expected to become a potential treatment strategy for SCI.
Collapse
|
2
|
Bel JS, Tai TC, Khaper N, Lees SJ. Mirabegron: The most promising adipose tissue beiging agent. Physiol Rep 2021; 9:e14779. [PMID: 33650753 PMCID: PMC7923552 DOI: 10.14814/phy2.14779] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 02/05/2021] [Accepted: 02/06/2021] [Indexed: 01/16/2023] Open
Abstract
Accumulation of white adipose tissue (WAT) underlies the obesity epidemic, leading to current therapeutic techniques that are being investigated for their ability to activate/“beige” this tissue. Adipose tissue (AT) beiging has been reported through intermittent cold exposure (CE), exercise, and β3‐Adrenergic Receptor (β3AR) agonists. But how AT beiging can help in the treatment of metabolic disorders like obesity and type 2 diabetes (T2D) remains largely unexplored. This review summarizes recent research on the use of β3AR agonist, mirabegron (Myrbetriq®), in stimulating beiging in AT. Researchers have only recently been able to determine the optimal therapeutic dose of mirabegron for inducing beiging in subcutaneous/ inguinal WAT, where the benefits of AT activation are evident without the undesired cardiovascular side effects. To determine whether the effects that mirabegron elicits are metabolically beneficial, a comparison of the undisputed findings resulting from intermittent CE‐induced beiging and the disputed findings from exercise‐induced beiging was conducted. Given the recent in vivo animal and clinical studies, the understanding of how mirabegron can be metabolically beneficial for both lean and obese individuals is more clearly understood. These studies have demonstrated that circulating adipokines, glucose metabolism, and lipid droplet (LD) size are all positively affected by mirabegron administration. Recent studies have also demonstrated that mirabegron has similar outcomes to intermittent CE and displays more direct evidence for beiging than those produced with exercise. With these current findings, mirabegron is considered the most promising and safest β3AR agonist currently available that has the potential to be used in the therapeutic treatment of metabolic disorders, and future studies into its interaction with different conditions may prove to be useful as part of a treatment plan in combination with a healthy diet and exercise.
Collapse
Affiliation(s)
- Jocelyn S Bel
- Biotechnology Program, Lakehead University, 955 Oliver Road Thunder Bay, ON, Canada
| | - T C Tai
- Northern Ontario School of Medicine, 955 Oliver Road Thunder Bay, ON and 935 Ramsey Lake Road, Sudbury, ON, Canada.,Biology, Laurentian University, 935 Ramsey Lake Road, Sudbury, ON, Canada.,Chemistry and Biochemistry, Laurentian University, 935 Ramsey Lake Road, Sudbury, ON, Canada.,Biomolecular Sciences Program, Laurentian University, 935 Ramsey Lake Road, Sudbury, ON, Canada
| | - Neelam Khaper
- Northern Ontario School of Medicine, 955 Oliver Road Thunder Bay, ON and 935 Ramsey Lake Road, Sudbury, ON, Canada.,Biomolecular Sciences Program, Laurentian University, 935 Ramsey Lake Road, Sudbury, ON, Canada.,Biology, Lakehead University, 955 Oliver Road Thunder Bay, ON, Canada
| | - Simon J Lees
- Northern Ontario School of Medicine, 955 Oliver Road Thunder Bay, ON and 935 Ramsey Lake Road, Sudbury, ON, Canada.,Biology, Lakehead University, 955 Oliver Road Thunder Bay, ON, Canada
| |
Collapse
|